Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

To assess the efficacies and potential predictors of a corticosteroid switch in metastatic castrationresistant prostate cancer (mCRPC) patients with biochemical progression on abiraterone acetate plus prednisone (A + P).